160 related articles for article (PubMed ID: 35697228)
1. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
[TBL] [Abstract][Full Text] [Related]
2. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
4. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
5. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
6. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
Agarwal P; Aiyer HM
Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract][Full Text] [Related]
8. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
[TBL] [Abstract][Full Text] [Related]
9. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
10. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
11. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis.
Lu VM; Alvi MA; McDonald KL; Daniels DJ
J Neurosurg Pediatr; 2018 Nov; 23(3):308-316. PubMed ID: 30544362
[TBL] [Abstract][Full Text] [Related]
12. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
13. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases.
Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W
World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860
[TBL] [Abstract][Full Text] [Related]
15. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
17. H3 K27M-mutant diffuse midline gliomas in different anatomical locations.
Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D
Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing of anaplastic ependymoma and H3K27M-mutant diffuse midline glioma.
Zang D; Dong Z; Liu Y; Chen Q
BMC Neurol; 2024 Feb; 24(1):74. PubMed ID: 38383423
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
[TBL] [Abstract][Full Text] [Related]
20. [Diffuse midline glioma with H3K27 alteration in adults: a clinicopathological analysis].
Yang QY; Li MN; Chen TY; Liu C; Li X; Shi ZM; Pan MH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):376-383. PubMed ID: 36973199
[No Abstract] [Full Text] [Related]
[Next] [New Search]
